Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Novo Nordisk A/S Common Stock (NY:NVO)

54.30 -0.48 (-0.89%)
Streaming Delayed Price Updated: 2:14 PM EDT, Aug 20, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Novo Nordisk A/S Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
92 93 Next >
Under Pressure: Palantir and Viking Therapeutics Face Investor Scrutiny
The financial markets are a dynamic arena where fortunes can shift rapidly, and the past week has seen two prominent companies, Palantir Technologies Inc. (NYSE: PLTR) and Viking Therapeutics (NASDAQ:... 
Via MarketMinute
Topics Artificial Intelligence
Corporate Wins: Intel, Palo Alto Networks, and Novo Nordisk Drive Market Optimism
In a week marked by a surge of positive corporate news, three industry giants—Intel, Palo Alto Networks, and Novo Nordisk—have delivered significant boosts to investor confidence, signaling robust... 
Via MarketMinute
Topics Artificial Intelligence Economy
Novo Nordisk Freezes Hiring As Wegovy Faces Copycats
Novo Nordisk may pursue layoffs as its new CEO focuses on efficiency while facing intensifying obesity drug competition. 
Via Benzinga
Topics Workforce
Health Canada Approves Novo’s Ozempic to Reduce Risk Of Kidney Function Decline, Cardiovascular Death
Via Stocktwits
Contact Levi & Korsinsky by September 30, 2025 Deadline to Join Class Action Against Novo Nordisk A/S (NVO)
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Fraud Lawsuit
Contact Levi &amp; Korsinsky by September 30, 2025 Deadline to Join Class Action Against Novo Nordisk A/S (NVO)
Via TheNewswire.com
Topics Fraud Lawsuit
Novo Nordisk Freezes Hiring To Cut Costs, Says Report: Retail Sees Stock Surpassing $100-Mark In A Year
Novo’s website currently shows multiple job openings in the U.S. and mainland China, but merely eight open positions in Denmark. 
Via Stocktwits
1 Reason to Buy NVO
There's more to the company's leading product than meets the eye. 
Via The Motley Fool
Viking's 42% Plunge Splits Experts—A '$129 Strong Buy' Or 'Clearly Inferior' Drug?
Viking (VKTX) stock plunged 42% after its obesity pill trial. Experts are split: some call it a $129 Strong Buy, others say it's inferior. 
Via Benzinga
Viking Therapeutics Plummets as Oral Obesity Drug Trial Raises Tolerability Concerns
San Diego, CA – Viking Therapeutics (NASDAQ: VKTX) experienced a dramatic stock decline today following the release of disappointing clinical trial results for its highly anticipated oral tablet... 
Via MarketMinute
Ozempic Gains First Approval In Canada For Kidney Disease And Cardiovascular Death Risk
Health Canada approved Ozempic for type 2 diabetes patients with chronic kidney disease after positive FLOW trial results. 
Via Benzinga
UnitedHealth Vs. Novo Nordisk: Which Healthcare Giant Fits Your Portfolio?
UnitedHealth is down 38.85% YTD; Novo Nordisk is down 38.59%. Yet, their underlying strategies couldn't be more distinct. 
Via Benzinga
Why Novo Nordisk Stock Popped Today
For a cheap GLP-1 weight loss stock like Novo Nordisk, almost any news can help the stock pop. 
Via The Motley Fool
Class Action Filed Against Novo Nordisk A/S (NVO) - September 30, 2025 Deadline to Join - Contact Levi & Korsinsky
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Fraud Lawsuit
Class Action Filed Against Novo Nordisk A/S (NVO) - September 30, 2025 Deadline to Join - Contact Levi &amp; Korsinsky
Via TheNewswire.com
Topics Fraud Lawsuit
Viking Therapeutics Crashes 35% On Mixed Results For Its Weight-Loss Pill
Shares lost more than a third of their value after Viking unveiled mixed results for its oral VK2735. 
Via Investor's Business Daily
3 Undervalued Healthcare Stocks You Can Buy Now and Hold Long-Term
The healthcare industry is one of the laggards of 2025. 
Via The Motley Fool
GoodRx Holdings Surges 5% After Hours on Novo Nordisk Partnership for $499 Monthly Ozempic, Wegovy Access
GoodRx stock rose 5.08% after it partnered with Novo Nordisk to offer Ozempic and Wegovy at a flat $499 monthly price for self-paying patients. 
Via Benzinga
Insiders Trade Millions in NVIDIA-Linked Navitas, Hims, & Shift4
A chip stock that recently partnered with NVIDIA. Now, a key company insider is buying over $160 million in shares, a bullish signal to investors. 
Via MarketBeat
Topics Artificial Intelligence
Autonomous Vehicles Hit an Inflection Point; GPT-5 Is Here
Motley Fool Money checks in on some stock market news. 
Via The Motley Fool
Topics Economy
10 Health Care Stocks With Whale Alerts In Today's Session
 
Via Benzinga
Stocks Muted Ahead Trump-Zelenskyy Meeting, First Solar Jumps: What's Moving Markets Monday?
Investor risk sentiment paused at the start of the week, as markets awaited details expected to emerge later when President Donald Trump meets with Ukrainian President Volodymyr Zelenskyy and European... 
Via Benzinga
Topics Government
Dayforce, Applied Digital, GoodRx, First Solar, TeraWulf: Stocks Making The Biggest Moves Today
Dayforce shares skyrocketed 26% in Monday’s midday trade after reports suggested that private equity firm Thoma Bravo is in talks to acquire the human resources firm. 
Via Stocktwits
Topics Artificial Intelligence ETFs Economy
Novo Nordisk Surges On Wegovy Win, Eyes Bullish Rebound Near 52-Week Lows
Novo Nordisk is showing signs that a comeback might be on the horizon after it hit the lows of its 52-week trading range. 
Via Benzinga
Ozempic And Wegovy Now Available Through GoodRx At Reduced Self-Pay Price, Stock Skyrockets
GoodRx and Novo Nordisk launch a $499 monthly self-pay option for Ozempic and Wegovy, expanding access at 70,000 pharmacies across the U.S. 
Via Benzinga
Market Movers: UnitedHealth, Intel, and Novo Nordisk Among Top Performers Reshaping the Financial Landscape
The financial markets are abuzz with significant movements across various sectors, driven by a confluence of strategic investments, groundbreaking regulatory approvals, and the enduring influence of... 
Via MarketMinute
Topics Artificial Intelligence Economy Government
Why Novo Nordisk Stock Popped Monday
Novo Nordisk stock looks so cheap, any good news at all can make it pop. 
Via The Motley Fool
Novo Nordisk Stock Surges After Pharma Major Cuts Ozempic Cost to $499 Per Month For Self-Paying Patients
The new offer aims to assist Type 2 diabetes patients who are uninsured or choose to self-pay, and may potentially face prices at or above wholesale cost. 
Via Stocktwits
Novo Nordisk Pops On A New Wegovy Approval, Dragging Hard On Madrigal Pharma
The FDA will allow patients with MASH to undergo Wegovy treatment, hampering the only other company with an approved MASH drug. 
Via Investor's Business Daily
Shareholders That Lost Money on Novo Nordisk A/S (NVO) Urged to Join Class Action - Contact Levi & Korsinsky to Learn More
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Fraud Lawsuit
< Previous 1 2 3 4 5 6 7 8 9
...
92 93 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.